THE SMART INTRAOCULAR LENS PARADOX: A CRITICAL REASSESSMENT OF MARKETED BENEFITS, UNDERREPORTED ADVERSE EFFECTS, AND THE COMMERCIALIZATION OF CATARACT SURGERY

Purpose: To critically examine the evidence base underlying smart intraocular lens (IOL) marketing claims, quantify the magnitude of underreported adverse effects, evaluate the role of commercial incentives in shaping clinical adoption, and argue that the designation “smart” constitutes a marketing construct rather than a meaningful clinical distinction.

Methods: A critical narrative review was conducted synthesizing evidence from independent (non-manufacturer-sponsored) clinical outcome studies, systematic reviews, explantation registries, patient-reported outcome data, medicolegal case analyses, regulatory documentation, and financial disclosures in the smart IOL literature. Satisfaction and adverse event data were disaggregated by sponsorship sources to evaluate reporting bias.

Results: Manufacturer-sponsored trials report satisfaction rates exceeding 90–98%, while independent tertiary referral studies document dissatisfaction in up to 94.7% of referred patients, with persistent photic phenomena (halos, glare, starbursts, diplopia) affecting 43–95% of recipients depending on assessment methodology. The Cochrane systematic review confirms significantly elevated risks of glare (RR 1.41) and halos (RR 3.58) relative to monofocal IOLs. Explantation rates among dissatisfied patients range from 0.85% to 7%, with neuroadaptation failure; an inherent consequence of simultaneous vision optics, identified as a leading cause. Financial analysis reveals that smart IOLs generate per-procedure revenue increases of 200–500% over standard monofocal implantation, creating structural incentives that compromise objective patient counseling. Critically, the evidence base upon which smart IOLs were approved systematically excludes the patients most likely to experience complications, inflating apparent efficacy while masking real-world failure rates.

Conclusions: The smart IOL industry operates on a business model that conflates technological sophistication with clinical superiority. The evidence does not support the claim that smart IOLs represent a categorically better option for the majority of cataract patients. A substantial and inadequately disclosed minority of recipients experience degraded visual quality, persistent dysphotopsia, and neuroadaptation failure; outcomes that would not have occurred with monofocal implantation. The “smart” designation functions primarily as a pricing and marketing mechanism rather than a reliable indicator of superior patient outcomes.